Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AIM-CD
NL-OMON51296Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Sep 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ABBV-154 in Crohn's disease (6 arms), sponsored by AbbVie Inc. Primary endpoint: Endoscopic response at Week 12. Started Sep 2022; status: completed.
02
Drugs
ABBV-154
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON51296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51296.